This suggests that holding GLP-1 RAs in diabetics is likely to reduce the risk for gastric residues in diabetic patients with and without neuropathy but is unlikely to affect gastrointestinal transit times in patients with significant diabetic neuropathy. This evidence concerns the gene GLP1R and diabetic neuropathy.